Imunon, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Imunon, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2015 | Dec 31, 2015 | $125.0K | Mar 30, 2016 |
| FY2015 | Sep 30, 2015 | $125.0K | Mar 30, 2016 |
| FY2015 | Mar 31, 2015 | $125.0K | Mar 30, 2016 |
| FY2015 | Dec 31, 2014 | $125.0K | Mar 30, 2016 |
| FY2015 | Sep 30, 2014 | $125.0K | Mar 30, 2016 |
| FY2015 | Jun 30, 2014 | $125.0K | Mar 30, 2016 |
| FY2015 | Mar 31, 2014 | $125.0K | Mar 30, 2016 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2023 | Dec 31, 2022 | $500.0K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $500.0K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $500.0K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $500.0K | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $500.0K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $500.0K | Mar 29, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.50M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($18.62M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($19.51M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($35.90M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($20.77M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($21.48M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($16.85M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($11.88M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($20.40M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($22.05M) | Mar 27, 2018 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($14.65M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($19.13M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($21.03M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($24.92M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($21.01M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($18.49M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($20.57M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($21.07M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($18.47M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($20.65M) | Mar 27, 2018 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.78M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $11.64M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $11.29M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $11.73M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $10.62M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $11.34M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $13.07M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $11.87M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $13.08M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $14.62M | Mar 27, 2018 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($13.90M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($18.85M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($19.02M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($23.10M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($16.22M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($15.62M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($20.26M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($7.04M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($16.64M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($18.38M) | Mar 27, 2018 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $280.6K | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $29.5K | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $451.8K | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $267.8K | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $311.6K | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $19.1K | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $349.2K | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $138.4K | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $38.6K | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $62.5K | Mar 27, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.29M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $9.72M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $21.92M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $43.98M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $74.05M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $37.53M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $38.28M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $46.86M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $47.51M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $30.85M | Mar 27, 2018 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $5.23M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.47M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $8.53M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $14.65M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $18.25M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $18.92M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $23.72M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $25.99M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $20.81M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $24.12M | Mar 27, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.06M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $4.24M | Mar 31, 2026 |
| FY2025 | Dec 31, 2023 | $13.39M | Mar 31, 2026 |
| FY2024 | Dec 31, 2022 | $29.33M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $55.80M | Mar 28, 2024 |
| FY2022 | Dec 31, 2020 | $18.61M | Mar 30, 2023 |
| FY2021 | Dec 31, 2019 | $14.56M | Mar 31, 2022 |
| FY2020 | Dec 31, 2018 | $20.86M | Mar 19, 2021 |
| FY2019 | Dec 31, 2017 | $26.70M | Mar 25, 2020 |
| FY2018 | Dec 31, 2016 | $6.73M | Mar 29, 2019 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2021 | Dec 31, 2020 | $1.98M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $1.98M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $1.98M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $1.98M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $1.98M | Mar 27, 2018 |
| FY2016 | Dec 31, 2015 | $1.98M | Mar 24, 2017 |
| FY2015 | Dec 31, 2014 | $1.98M | Mar 30, 2016 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($421.30M) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | ($406.80M) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | ($388.18M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($368.67M) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | ($332.77M) | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | ($312.00M) | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | ($290.52M) | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | ($273.67M) | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | ($261.78M) | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | ($241.38M) | Mar 27, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $8.78M | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | $5.87M | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | $5.84M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $11.49M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | $19.59M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | $17.16M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | $6.88M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | $13.35M | Mar 25, 2020 |
| FY2018 | Dec 31, 2017 | $11.44M | Mar 29, 2019 |
| FY2017 | Dec 31, 2016 | $2.62M | Mar 27, 2018 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Dec 31, 2022 | $5.96M | Mar 30, 2023 |
| FY2021 | Sep 30, 2021 | $5.85M | Mar 31, 2022 |
| FY2020 | Dec 31, 2020 | $5.05M | Mar 19, 2021 |
| FY2019 | Dec 31, 2019 | $9.80M | Mar 25, 2020 |
| FY2018 | Dec 31, 2018 | $9.42M | Mar 29, 2019 |
| FY2013 | Dec 31, 2013 | $5.00M | Mar 13, 2014 |
| FY2012 | Dec 31, 2012 | $5.00M | Mar 18, 2013 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (16) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | (3) | Mar 30, 2023 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | (6) | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | (16) | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | (2) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | (5) | Mar 28, 2024 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 3.42M | Mar 31, 2026 |
| FY2025 | Jul 25, 2025 | 15 | Mar 31, 2026 |
| FY2025 | Dec 31, 2024 | 966,712 | Mar 31, 2026 |
| FY2024 | Dec 31, 2023 | 9.40M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 7.44M | Mar 28, 2024 |
| FY2023 | Feb 28, 2022 | 86.56M | Mar 28, 2024 |
| FY2022 | Dec 31, 2021 | 5.77M | Mar 30, 2023 |
| FY2021 | Dec 31, 2020 | 2.71M | Mar 31, 2022 |
| FY2020 | Dec 31, 2019 | 23.26M | Mar 19, 2021 |
| FY2019 | Dec 31, 2018 | 18.83M | Mar 25, 2020 |